白蛋白结合型紫杉醇与紫杉醇脂质体治疗复发性卵巢癌近期疗效与安全性分析
发布时间：2018-08-26 09:34
【摘要】：目的:探讨白蛋白结合型紫杉醇(PTX)与PTX脂质体(力扑素)治疗复发性卵巢癌的近期疗效及不良反应。方法:回顾性分析采用PTX治疗的90例复发性卵巢癌患者的临床资料,其中应用白蛋白结合型PTX联合奈达铂治疗30例为PTX结合型组,应用PTX脂质体联合奈达铂治疗60例为PTX脂质体组。比较两组癌抗原125(CA125)下降情况和肿瘤病灶缩小情况,以及不良反应的差异。结果:PTX结合型组CA125下降的有效率(63.3%)高于PTX脂质体组(41.7%);PTX结合型组病灶缩小的有效率(54.5%)高于PTX脂质体组(23.8%),差异均有统计学意义(P0.05)。PTX结合型组腹泻、呕吐、白细胞减少Ⅲ~Ⅳ级的不良反应发生率均少于PTX脂质体组(P0.05),两组神经毒性发生率比较,差异无统计学意义(P0.05)。结论:白蛋白结合型PTX联合奈达铂与PTX脂质体联合奈达铂治疗复发性卵巢癌相比,其临床近期疗效提高,严重不良反应率较低,使用方便,值得推广。
[Abstract]:Aim: to investigate the efficacy and side effects of albumin bound paclitaxel (PTX) and PTX liposome (telopontin) in the treatment of recurrent ovarian cancer. Methods: the clinical data of 90 patients with recurrent ovarian cancer treated with PTX were retrospectively analyzed. 30 patients were treated with albumin binding PTX combined with nedatin. 30 patients were treated with PTX binding type. 60 cases were treated with PTX liposome combined with niedaplatin as PTX liposome group. The decrease of cancer antigen 125 (CA125) and the reduction of tumor focus, and the difference of adverse reactions were compared between the two groups. Results the effective rate of CA125 reduction in the CA125 binding group (63.3%) was higher than that in the PTX liposome group (41.7%), and the effective rate of lesion reduction in the PTX-binding group (54.5%) was higher than that in the PTX liposome group (23.8%). The difference was statistically significant (P0.05). The incidence of adverse reactions in grade 鈪，
本文编号：2204455
[Abstract]:Aim: to investigate the efficacy and side effects of albumin bound paclitaxel (PTX) and PTX liposome (telopontin) in the treatment of recurrent ovarian cancer. Methods: the clinical data of 90 patients with recurrent ovarian cancer treated with PTX were retrospectively analyzed. 30 patients were treated with albumin binding PTX combined with nedatin. 30 patients were treated with PTX binding type. 60 cases were treated with PTX liposome combined with niedaplatin as PTX liposome group. The decrease of cancer antigen 125 (CA125) and the reduction of tumor focus, and the difference of adverse reactions were compared between the two groups. Results the effective rate of CA125 reduction in the CA125 binding group (63.3%) was higher than that in the PTX liposome group (41.7%), and the effective rate of lesion reduction in the PTX-binding group (54.5%) was higher than that in the PTX liposome group (23.8%). The difference was statistically significant (P0.05). The incidence of adverse reactions in grade 鈪，
本文编号：2204455
本文链接：https://www.wllwen.com/yixuelunwen/fuchankeerkelunwen/2204455.html
最近更新
教材专著
